 | |
| Clinical data | |
|---|---|
| Trade names | Nurtec ODT, Vydura |
| Other names | BHV-3000, BMS-927711 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620031 |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Calcitonin gene-related peptide receptor antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H28F2N6O3 |
| Molar mass | 534.568 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rimegepant, sold under the brand nameNurtec ODT among others, is amedication used for the acute treatment ofmigraine with or withoutaura in adults and the prophylactic/ preventive treatment of episodic migraine in adults.[8][10] It is takenby mouth to dissolve on orunder the tongue.[8] It works by blockingCGRP receptors.[11]
In the United States, rimegepant was approved for treating acute migraine in February 2020,[12] and its approval was extended to preventing episodic migraine in June 2021.[8] It is produced and marketed byPfizer.[13] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel.[14][15] It was approved for medical use in Canada in December 2023.[4] In the United Kingdom, rimegepant is approved by NICE for the prophylaxis and treatment of acute migraine in adults.[16]
Rimegepant isindicated for the treatment of acute migraine with or without aura in adults and for the preventative treatment of episodic migraine in adults.[8][10][9]
Rimegepant is a small moleculecalcitonin gene-related peptide (CGRP) receptor antagonist.[11]
Rimegepant wasdeveloped by Biohaven Pharmaceuticals, which markets the drug in the United States after receivingFDA approval in February 2020.[12][17] Approval was based on evidence from oneclinical trial of 1,351 subjects with migraine headaches.[10]
In February 2022, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine.[18] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC.[18] Rimegepant was approved for medical use in the European Union in April 2022.[9][19]
Pfizer reported revenue ofUS$928 million for Nurtec ODT/Vydura in 2023.[20]
Marketing
American singer, songwriter and actressLady Gaga is featured in advertisements for rimegepant, under the Nurtec ODT brand. Her involvement sparked criticism of the role of celebrities in pharmaceutical endorsements.[21]
This article incorporates text from this source, which is in thepublic domain.
